Biotts is pleased to announce the issuance of US Patent No. 12,201,621 B2 on January 21, 2025. This patent covers a novel topical anesthetic formulation, MTC-A4, which combines tetracaine and lidocaine in a unique delivery system designed to provide an improved treatment option compared to existing therapies like Pliaglis.

Biotts is excited to be a part of Biotech Showcase 2025, taking place January 13-15 in San Francisco! This leading industry event brings together key players in the biotech world – from investors to innovators – to explore the latest advancements and forge new partnerships.

We’re thrilled to share that Biotts has been selected as one of the finalists for the Investor Pitch at the RESI Europe London Edition on December 4, 2024.

Thank you to everyone who joined us at SAE’s 3rd Annual Transdermal and Microneedle Drug Delivery Conference in London on November 11-12.

We are excited to announce that Biotts will be attending SAE’s 3rd Annual Transdermal and Microneedle Drug Delivery Conference in London, UK, on November 11-12, 2024!

The 2024 PODD Conference in Boston brought together leaders and innovators from across the pharmaceutical, biotech, and drug delivery sectors. We were honored to participate and showcase Biotts’ latest advancements in transdermal drug delivery.